Literature DB >> 18295551

Molecular evolution of the prostate cancer susceptibility locus RNASEL: evidence for positive selection.

Kyle Summers1, Bernard Crespi.   

Abstract

Recent research implicates viral infection as a factor that may contribute to the risk of prostate cancer. Allelic variation at the RNASEL locus is associated with the risk of infection by a newly discovered retrovirus called XMRV, and with hereditary risk of prostate cancer. This evidence suggests that the RNASEL locus has undergone antagonistic coevolution with the retrovirus over evolutionary time. If this is the case, then both the RNASEL locus and the retrovirus should show evidence of positive selection. Here we use molecular-evolutionary methods to investigate the prediction that the RNASEL locus will exhibit evidence of positive selection. We find evidence that positive selection has acted on this locus over evolutionary time. We further find, using a Bayesian estimation procedure, that Asp541Glu, which was found to be associated with prostate cancer risk in Caucasians in a recent meta-analysis, shows an elevated probability of positive selection. Previous studies provide evidence for rapid evolution of the infection-mediating gag gene in the XMRV retrovirus. Taken together, these results suggest that antagonistic coevolution may have occurred between a specific host locus involved in immune defense (RNASEL) and a viral pathogen. In turn, genetic variation associated with this apparent coevolution may influence susceptibility to prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295551     DOI: 10.1016/j.meegid.2008.01.004

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  7 in total

1.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.

Authors:  Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

2.  Genetic variation in RNASEL associated with prostate cancer risk and progression.

Authors:  Mara S Meyer; Kathryn L Penney; Jennifer R Stark; Fredrick R Schumacher; Howard D Sesso; Massimo Loda; Michelangelo Fiorentino; Stephen Finn; Richard J Flavin; Tobias Kurth; Alkes L Price; Edward L Giovannucci; Katja Fall; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2010-06-24       Impact factor: 4.944

3.  RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Chao Qin; Yong Wang; Qiang Cao; Jun-Feng Wei; Yao-Jun Zhou; Ning-Han Feng; Wei Zhang
Journal:  Mol Biol Rep       Date:  2011-01-09       Impact factor: 2.316

4.  Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.

Authors:  Ilir Agalliu; Suzanne M Leanza; Lorie Smith; Jeffrey M Trent; John D Carpten; Joan E Bailey-Wilson; Robert D Burk
Journal:  Prostate       Date:  2010-11-01       Impact factor: 4.104

5.  Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells.

Authors:  Sushma Bhosle; Suganthi Suppiah; Ross Molinaro; Yuying Liang; Rebecca Arnold; William Diehl; Natalia Makarova; Jerry Blackwell; John Petros; Dennis Liotta; Eric Hunter; Hinh Ly
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

6.  A history of recurrent positive selection at the toll-like receptor 5 in primates.

Authors:  Gabriela Wlasiuk; Soofia Khan; William M Switzer; Michael W Nachman
Journal:  Mol Biol Evol       Date:  2009-01-29       Impact factor: 16.240

7.  Evidence from 40 Studies that 2 Common Single-Nucleotide Polymorphisms (SNPs) of RNASEL Gene Affect Prostate Cancer Susceptibility: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Compliant Meta-Analysis.

Authors:  Jun Xia; Rulin Sun
Journal:  Med Sci Monit       Date:  2019-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.